Dr. Andreas Meyer-Lindenberg as New Editor-in-Chief of journal: European Neuropsychopharmacology
The European College of Neuropsychopharmacology is pleased to announce Professor Andreas Meyer-Lindenberg, MD, Director of the Central Institute of Mental Health in Mannheim, and Chair of Psychiatry at the University of Heidelberg, as the new editor-in-chief of European Neuropsychopharmacology (ENP), the official journal of the European College of Neuropsychopharmacology (ECNP). Meyer-Lindenberg was jointly appointed by the College and the journal's publisher Elsevier, for a three year term. He takes over from Professor Michael Davidson, MD, Chairman of Psychiatry at Tel Aviv University, who led the journal for the maximum term of six years and presided over a strong increase in the journals impact and reach.
The European College of Neuropsychopharmacology (ECNP) is Europe's leading interdisciplinary forum for the science and treatment of disorders of the brain. In its mission to promote the communication and cross- fertilisation of high-quality experimental and clinical research across the field of neuroscience, the journal ENP plays a critical role.
Meyer-Lindenberg's research interests focus on the development of novel treatments for severe psychiatric disorders, especially schizophrenia, through an application of multimodal neuroimaging, genetics and environmental science to characterize brain circuits underlying the risk for mental illness and cognitive dysfunction. He is a member of the Executive Board of the ECNP and has been an Associate Editor of the journal for four years prior to his appointment.
"There has rarely been a time in which so many scientific advances in neuroscience are available to advance the treatment and prevention of neuropsychiatric disorders," said Professor Meyer-Lindenberg. "I am excited to work with an expert team of editors to consolidate and expand the position of ENP as a premier journal for the best in translational research in our field".
Guy Goodwin, FMedSci, President of ECNP, said, "We are very grateful of Professor Michael Davidson for the high standards of collegiality and quality he has set during his outstanding tenure as editor. He has worked with closely with Andreas to ensure a natural and seamless transition and Andreas is the ideal person to lead ENP in the next phase of its evolution, at a time of growing optimism in applied neuroscience."
"We congratulate Professor Meyer-Lindenberg on his new role with the journal, and look forward to working closely with him as the journal develops and grows," said Herb Niemirow, Publisher at Elsevier.
The European College of Neuropsychopharmacology (ECNP) is an independent scientific association dedicated to translating advances in the understanding of brain function and human behaviour into better treatments and enhanced public health. ECNP organises a wide range of scientific and educational activities, programmes and events across Europe, promoting exchange of high-quality experimental and clinical research and fostering young scientists and clinicians in the field. The annual ECNP Congress attracts around 4,000-7,000 scientists and clinicians from across the world to discuss the latest advances in brain research in Europe's largest meeting on brain science. http://www.ecnp.eu/about-ecnp.aspx
About European Neuropsychopharmacology
European Neuropsychopharmacology is the official journal of the European College of Neuropsychopharmacology (ECNP). It publishes articles and commentary on neuroscientific advances relevant for the treatment of neuropsychiatric disorders and thus advances the college's mission to translate new knowledge on fundamental disease mechanisms into new medicines and clinical applications. The journal belongs to the top twenty worldwide in psychiatry and currently has an impact factor of 5.395.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com